Skip to main content
Equibles
PFE logo

PFE · Pfizer Inc

Track PFE — free

Use PFE with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about PFE

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$28.26 +1.01 (+3.69%)
Market Cap
$155.52B
Shares
5.70B

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$27.25 Open$27.15 Day$27.10–27.40 52W close$23.60–28.55 Avg vol 30d39.1M Short int161.5M · 2.8% float · 4.2d Short vol24% Last earningsAug 4, 2026 DataNov 2020–Aug 2026 Filing10-Q · Aug 4

Raw chart and full-history price indicators begin at the captured split on Nov 17, 2020; bars on opposite sides are not compared.

Up next

Next earnings call
Nov 3, 2026 Est · unconfirmed · in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 4, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Buy Momentum Strong Sentiment Neutral Fundamentals Weak Quant / Vol Low
      Market backdrop VIX 15.8 · calm Equity put/call 0.64
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +5%
      above
      Price vs 50-day avg +8%
      above
      RSI (14) 69
      neutral
      MACD trend Positive
      52-week position 74%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Strong
      1-month return +9%
      trailing
      6-month return +1%
      trailing
      YTD return +9%
      this year
      Relative strength −10%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $25 › 200d $26 — 200d above 50d
      Institutional flow Distributing
      -5% holders QoQ · +142 funds added
      Insider flow Accumulating
      Net +$2.8M over 90 days · 25% sells
      Short interest Falling
      2.83% of float · ▼ -1.4% MoM · 4.2 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr low
      2,822 holders — near 3-yr low, contrarian setup
      Squeeze score 59
      elevated · 0–100
      Fundamentals
      Weak
      Revenue growth −2%
      Y/Y
      EPS growth −4%
      Y/Y
      Free cash flow $9.1B
      Valuation P/E 35.9
      in line
      Buyback $3.3B
      remaining
      Balance sheet $63.7B
      net debt
      Quant / Vol
      risk profile
      Low
      Volatility 24%
      annualized · 1-yr
      Max drawdown −17%
      past year
      ATR 2.0%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 3 of last 3
      Latest guidance · from the 8-K filed May 5, 2026
      Revenues · full-year 2026 $59.5B – $62.5B
      Prior guidance period ended · from the 8-K filed Nov 4, 2025
      Revenues · full-year 2025 $61B – $64B
      Guided vs delivered · last 3 settled
      Revenues full-year 2025
      guided $61B – $64B
      $62.58B In line
      Revenues full-year 2024
      guided $58.5B – $61.5B
      $63.63B Beat +6.0%
      Total company full-year 2023 revenues full year 2023
      guided $58B – $61B
      $59.55B In line

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      0 · 4 · 3
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +5% Bullish
      Price vs 50-day avg
      +8% Bullish
      RSI (14)
      69 Neutral
      MACD trend
      Positive Bullish
      52-week position
      74% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) No cross
      50d $25 › 200d $26 — 200d above 50d
      Institutional flow Distributing
      -5% holders QoQ · +142 funds added
      Insider flow Accumulating
      Net +$2.8M over 90 days · 25% sells
      Short interest Falling
      2.83% of float · ▼ -1.4% MoM · 4.2 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr low
      2,822 holders — near 3-yr low, contrarian setup
      Price context
      position in its 52-week range
      Range low $24 Now $27 · 74% Range high $29
      vs 200-day avg +5% vs 50-day avg +8%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Versus peers

      Drug Manufacturers - General — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      PFE
      Pfizer Inc
      this stock
      		$155.52B +9.4% -1.6% 35.9 2.8%
      LLY
      ELI LILLY & Co
      		 $1.11T +14.1% +44.7% 39.7 1.0%
      JNJ
      Johnson & Johnson
      		 $632.29B +31.0% +6.0% 30.5 1.1%
      ABBV
      AbbVie Inc.
      		 $457.54B +13.3% +8.6% 73.1 1.3%
      MRK
      Merck & Co., Inc.
      		 $335.46B +28.4% +1.3% 108.8 1.1%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      2,822
      % held
      69.9%
      Net QoQ
      +42.3M sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      1,095
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      161.5M
      Days to cover
      4.2d
      Change
      -2.3M sh
      View
      Short Volume
      Short vol %
      24%
      As of
      Aug 19, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      884
      Value
      $22.3K
      As of
      Jul 29, 2026
      View
      Off-Exchange
      Off-exchange %
      55.2%
      Week of
      Jul 13, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Cluster buy
      Net (90d)
      +$2.8M
      Buyers / Sellers
      3 / 1
      Buyers Sellers
      View
      Congressional Trades Sell
      Member
      Thomas H Tuberville
      Amount
      $15.0K–$50.0K
      Traded
      Jun 8, 2026
      View
      Financials
      Financials
      Revenue (FY)
      $62.6B
      Net income (FY)
      $7.8B
      EPS diluted
      $1.36
      View
      Buybacks
      Authorized
      $6.8B
      Remaining
      $3.3B
      Spent Remaining
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 4, 2026
      This year
      12
      View
      Proposed Sales
      Value
      $1.4M
      Shares
      59.8K
      Filed
      May 23, 2025
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 4, 2026
      View
      Investor Relations
      Latest news
      Pfizer and Valneva’s Lyme Disease…
      Published
      Aug 14, 2026
      View

      Performance

      Raw-price comparisons begin at the captured split on Nov 17, 2020; windows that need an earlier baseline remain unavailable.

      5D 20D 120D MTD YTD
      PFE +2.4% +9.3% +0.6% +9.0% +9.4%
      SPY -0.4% +2.6% +10.7% +2.7% +12.5%
      vs SPY +2.8% +6.7% -10.1% +6.2% -3.1%

      Capital returns

      Latest dividend
      $0.43 / share · ex Jul 24, 2026
      Raised 2.4%
      Paid (TTM)
      $1.72 / share · 4 payouts
      Dividend yield (TTM, derived)
      6.31%
      Buyback program · as of Aug 4, 2026
      Authorized
      $6.80B
      Spent (derived)
      $3.50B
      Remaining
      $3.30B
      Spent Remaining

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 78003 CUSIP 717081103 13F (30d) 2432 filings 2340 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)